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Abstract
Background:  Zymosan-induced shock has been associated with an increased production of pro-
inflammatory cytokines and mediators, causing a generalized dysfunction of liver, lung and kidneys. Herein,
we investigate the effects of tyrphostin AG-490 on the early inflammation and on the late renal injury
provoked by zymosan injection.
Methods: Shock was induced by intraperitoneal injection of zymosan in a dose of 0.8–1.0 mg/g body
weight in BALB/c mice and 0.8 mg/g body weight in SCID mice. Tyrphostin AG-490 was administered
intraperitoneally in a dose of 5 mg/kg immediately after shock induction. Blood, peritoneal lavage and
kidneys were collected at certain time points after zymosan injection. The levels of MIP-1α, RANTES, IL-
6, IL-10, α1-antitrypsin and C5a in plasma were determined by ELISA. The number of IL-10-secreting cells
in peritoneum was assayed by ELISPOT. Kidney function was monitored by measurement of urine/plasma
creatinine levels and proteinuria. Histological assessment of renal injury was performed in a blinded fashion
after hematoxylin/eosin staining. Immunohistochemistry analyses were used to evaluate the expression of
C5aR, STAT1, STAT3 and the binding ability of IgGs in kidneys.
Results: Tyrphostin AG-490 attenuated the early phase of zymosan-induced shock via inhibition of MIP-
1α, RANTES and C5a plasma levels and via elevation of IL-10 in plasma. The drug increased IL-10
production in peritoneum and the number of IL-10-secreting peritoneal cells. AG-490 was able to retain
the time of coagulation and the level of α1-antitrypsin to normal values. At the late stage of shock, AG-
490 decreased scores of tubular injury, cell infiltration and glomerular lesions in parallel with diminished
creatinine plasma level and protein excretion. These beneficial effects of AG-490 were related to lowered
levels of circulating IL-6, MIP-1α and C5a, and to inhibited expression of STAT1, STAT3 and C5aR in
kidneys. The drug diminished the production of zymosan-specific IgG antibodies and hindered the
glomeruli from IgGs recognition.
Conclusion: Tyrphostin AG-490 reduced the magnitude of the initial inflammatory response in zymosan-
induced shock and prevented the development of severe kidney dysfunction. Our data suggest that the
drug might be used as a therapeutic approach in cases where shock is combined with acute renal injury.
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Background
Septic shock is a complex inflammatory disease associated
with a high rate of mortality. It starts with an over-
whelmed immune response to infectious agents or their
products in which the activated macrophages, neutrophils
and the complement system play important roles.
Cytokines and inflammatory mediators produced and
secreted at first hours can induce organ failure and dam-
age. Kidney involvement has been often observed in sep-
tic shock patients [1] and contributed to high mortality
rate [2,3]. While high levels of the pro-inflammatory TNF-
α and IL-6 favor the renal injury [4], IL-10 has a suppres-
sive effect and attenuates the kidney inflammation [5]. In
the model of zymosan-induced shock, kidney dysfunction
is mainly evaluated by measurement of organ size and of
serum creatinine level [6]. Recent report has shown an up-
regulated expression of IL-6, TNF-α and IL-1β mRNA in
kidneys during the middle phase of zymosan-induced
shock [7]. In this study, strongly elevated level of IL-10
mRNA determines the enhanced resistance of kidneys to
zymosan-induced inflammation. The renal tubular necro-
sis has been observed at the late stage of the disease [8],
but more investigations are required to fully describe the
kidney involvement in this animal model.
Zymosan is recognized by immune cells through Toll-like
receptors 2 and 6 (TLR2, TLR6) that trigger the MyD88-
mediated NF-kB activation and cytokine production
[9,10]. The binding of zymosan to the C-type lectin recep-
tors such as dectin-1 receptor induces phagocytocis [11].
Besides immune cells, zymosan can activate directly the
alternative complement pathway resulting in extensive
C5a generation [12]. Previously, we have observed that
lowered C5a levels in peritoneum and in circulation of
properdin-deficient mice improved the course of
zymosan-induced inflammation [13]. C5a increases neu-
trophil chemotaxis and the production of superoxide
ions, vasodilation and apoptosis [14]. It has also been
implicated in the pathology of human and animal renal
diseases [15] and recently, some therapeutic strategies are
pointed on the inhibition of C5a or its receptor [16].
Tyrphostin AG-490 is a JAK2 kinase inhibitor that targets
the cytokine-dependent STAT signalling pathway. The
drug has a beneficial effect in a model of autoimmune
encephalomyelitis [17] and inhibits the abnormal cell
proliferation in patients with lymphoblastic leukemia,
acute myeloid leukemia and Sezary syndrome [18,19].
The restriction of JAK/STAT pathway in macrophages by
AG-490 diminishes IFN-γ-induced nitric oxide synthase
expression and nitric oxide secretion, and inhibits TNF-α
production triggered by high mobility group box 1 pro-
tein (HMGB1) [20,21]. In respect to kidneys, AG-490
attenuates experimental nephritic syndrome and
ischemia/reperfusion kidney injury [22,23]. According to
our previous investigations AG-490 inhibited TLR4- and
TLR9-induced IL-12 and nitric oxide production by peri-
toneal macrophages and attenuated the liver abnormali-
ties in aseptic shock [24,25]. Herein, we have extended
our investigations and we have evaluated the effects of
AG-490 on zymosan-induced kidney dysfunction.
Methods
Reagents
Zymosan A from Saccharomyces cerevisiae (Sigma-Aldrich,
Munich, Germany) was suspended in endotoxin-free
water at a concentration of 40 mg/ml, homogenized by
sonic emulsification, autoclaved for 30 min and stored in
aliquots at -20°C. Tyrphostin AG-490 (2-Cyano-3-(3,4-
dihydroxyphenyl)-N-(benzyl)-2-propenamide) was
obtained from Sigma-Aldrich (Munich, Germany) and
was dissolved to 5 mg/ml in 75% ethanol, and frozen at -
20°C.
Animals
Female BALB/c or SCID mice, 8–10 weeks old weighing
20–25 g, were purchased from The Charles River Labora-
tories (Wilmington, Massachussets, USA). They were
maintained in specific pathogen free environment and
had free access to water and standard food. All experi-
ments were conducted in accordance with The National
Guideline for the Care and Use of Laboratory Animals
(Decree No 14/19.07.2000) and were approved by the
Animal Care Committee at the Institute of Microbiology,
Sofia.
Experimental design
Shock was induced by intraperitoneal injection of 1 mg/
g body weight of zymosan (0.5 ml) in BALB/c mice (n =
15/group/experiment). In our experiments we have used
female mice. Any differences in the development of dis-
ease between male and female animals have not been
reported. The stock solution of tyrphostin AG-490 was
diluted to 1 mg/ml in endotoxin-free phosphate-buff-
ered saline (PBS; Cambrex Bioscience, Verviers, Bel-
gium) and was administered intraperitoneally in a dose
of 5 mg/kg. The animals were treated with AG-490
immediately after the induction of shock. Control
groups received vehicle solution (0.5 ml) containing
1.2% ethanol in endotoxin-free PBS or 5 mg/kg AG-490.
The survival of mice was monitored for 21 days. Blood,
peritoneal lavage and kidneys were collected at certain
time points after shock induction. In another set of
experiments, shock was induced in mice with severe
combined immunodeficiency (SCID). SCID mice were
injected with zymosan in a dose of 0.8 mg/g body weight
because in our previous study the injection of 1 mg/g
body weight of zymosan caused 100% mortality within
24 h [26]. BALB/c mice were injected with the same dose
of zymosan. AG-490 was administered in a dose of 5 mg/
kg (n = 15/group/experiment). Blood and kidneys were
collected on day 21 of shock.Journal of Inflammation 2009, 6:13 http://www.journal-inflammation.com/content/6/1/13
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Preparation of peritoneal lavage and isolation of 
peritoneal cells
Peritoneal lavage was obtained 4 h after the injection of
zymosan (n = 5/group) by washing the peritoneal cavity
with 2 ml sterile RPMI-1640 medium (Biowhittaker™,
Cambrex, Verviers, Belgium). The supernatants were col-
lected after centrifugation at 1200 × g for 10 min and
immediately frozen at -70°C. The cell pellets were resus-
pended in RPMI-1640 medium containing 5% fetal calf
serum (FCS) and were dispensed in glass Petri dishes (5
ml/dish). After incubation for 1 h at 37°C, 5% CO2, the
non-adherent cells were carefully aspirated, washed with
PBS and counted. The adherent cells were gently detached
by scraping with a silicone rubber, washed and counted.
Both populations of peritoneal cells were resuspended in
10% FCS/RPMI-1640 at a concentration of 1.0 × 106 cells/
ml and were used in ELISPOT assay for determination of
IL-10-secreting cells.
Measurement of cytokines and chemokines
Blood was collected in heparin-containing glass tubes by
retro-orbital puncture (n = 5/group). Plasma was
obtained by centrifugation at 3000 × g for 10 min at 4°C,
and was frozen at -70°C. The levels of IL-10, IL-6, MIP-1α
and RANTES were measured in plasma and in peritoneal
lavage by ELISA. The quantitative ELISA kits (PeproTech
EC Ltd, London, UK) were with detection limits 47 pg/ml
for IL-10, 62 pg/ml for IL-6, 8 pg/ml for MIP-1α and 16
pg/ml for RANTES, respectively.
Detection of IL-10-secreting peritoneal cells
The number of IL-10-secreting peritoneal cells was deter-
mined by ELISPOT assay. Nitrocellulose-backed 96-well
microtiter plate (Millipore, Billerica, Massachussets, USA)
was coated with purified rabbit anti-mIL-10 antibody (10
μg/ml, PeproTech, London, UK). The plate was incubated
overnight at 4°C and then washed three times with PBS.
Non-adherent and adherent peritoneal cells (1.0 × 105
cells/well), and a positive control of recombinant IL-10
(250 μg/ml; 100 μl/well; PeproTech, London, UK) were
added at triplicates to the plate and were stimulated with
zymosan (20 μg/ml) for 18 h at 37°C. The cells were then
removed by washing with PBS and the unspecific binding
was blocked with 5% bovine serum albumin (BSA)/PBS
for 1 h at room temperature. The biotinylated rabbit anti-
mIL-10 antibody (0.250 μg/ml; 100 μl/well; PeproTech,
London, UK) was added for 2 h at room temperature. The
plate was washed and incubated with avidin peroxidase
conjugate (1:1000 diluted; 100 μl/well; PeproTech, Lon-
don, UK) for 30 min. The substrate solution containing 3-
amino-9-ethylcarbazole (200 μl/well; AEC; Sigma-
Aldrich, Munich, Germany) was used. The color reaction
was stopped with dH2O and air-dried overnight before
spot enumeration using a light microscope (Boeco, Ham-
burg, Germany) at 1 × 100 magnification. The results were
expressed as counted spots per 1.0 × 105 cells.
Detection of zymosan-specific IgG antibodies
The serum level of zymosan-specific IgG antibodies was
determined by ELISA as described [27]. ELISA 96 well test
plates (Greiner Bio-One GmbH, Essen, Germany) were
coated with zymosan (100 μg/well) in PBS, blocked with
2% BSA/PBS and incubated with serum samples (1:100
diluted) for 2 h at room temperature. The secondary per-
oxidase-conjugated anti-mouse IgG antibody (1:10 000
diluted; Sigma-Aldrich, Munich, Germany) was incubated
for 1 h at room temperature. The substrate o-phenylenedi-
amine (Sigma-Aldrich, Munich, Germany) was used to
develop the colorimetric reaction. The absorbance was
measured at 492 nm in a microplate reader (BioTek
Instruments Inc, Winooski, Vermont, USA). The data were
obtained using the Gen 5.0 software (BioTek Instruments
Inc). Samples were measured in triplicates and their
absorption was normalized to that of the control positive
serum. The results were expressed in relative units (RU) ±
standard deviation.
Measurement of plasma C5a
ELISA 96-well plates (Greiner Bio-One GmbH, Essen, Ger-
many) were coated with rat anti-mouse C5a antibodies
(BD Biosciences, Erembodegem, Belgium) overnight and
blocked with 2% BSA/PBS for 1 h at room temperature.
Plasma samples (diluted 1:5) and serial dilutions of C5a
(BD Biosciences, Erembodegem, Belgium) were added in
triplicates and incubated for 2 h at room temperature.
After washing, biotinylated rat anti-mouse C5a antibodies
(BD Biosciences, Erembodegem, Belgium) was added and
detected with avidin-peroxidase (1:1000, PeproTech EC
Ltd, London, UK). The results were calculated from a
standard curve plotting the absorbance values against the
concentrations of C5a and were expressed in picograms
per ml.
Coagulation time and plasma level of α1-antitrypsin
The level of α1-antitrypsin and the coagulation time were
determined as previously described [13,28].
Functional assessment of renal injury
Blood was collected at certain time points of zymosan
injection (n = 5/group). The plasma and urine creatinine
levels (milligrams per deciliter) were determined by alka-
line picric acid method using a standard laboratory kit
(Dialab, Wiener Neudorf, Austria). The protein level in
urine was measured by Bradford assay. The protein excre-
tion showing the glomerular filtration rate was expressed
as milligrams urinary proteins per milligrams urinary cre-
atinine.
Histolopathological assessment of renal injury
Kidneys were fixed in 10% paraformaldehyde/PBS (pH
7.4). The organs were embedded in paraffin and sections
with thickness 4 μm were cut by rotary microtome (Accu-
Cut® SRM™ Sacura Finetek, Tokyo, Japan). The slides wereJournal of Inflammation 2009, 6:13 http://www.journal-inflammation.com/content/6/1/13
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stained with hematoxylin and eosin (H&E) and were
examined with a light microscope (BM-180 T/PL, Boeco,
Hamburg, Germany) using a 1 × 100 or 1 × 400 lens.
Images were captured with a coupled device camera and
exported to Adobe Photoshop 7.0 (Adobe Systems,
Munich, Germany).
All histological assessments were performed in a blinded
protocol. The degree of renal injury was graded semi-
quantitatively in at least 30 cross-sections per mice
according following characteristics: glomerular lesions,
tubular vacuolization, tubular dilation, tubular necrosis
and leukocyte infiltration. The 5 score system was used:
score 1 = no abnormality, 2 = 10% injury; 3 = 25% injury;
4 = 50% injury; 5 = > 75% injury. The renal injury score
was calculated as an average score of the mean score for
each characteristic.
Immunohistochemistry
The expression of STAT1 and STAT3 in kidneys was evalu-
ated as previously described [25]. Kidney sections (4 μm)
were immersed in 3% H2O2/60% methanol for 10 min to
block endogenous peroxidase. After blocking of unspecific
binding with 5% BSA/PBS, the sections were incubated for
2 h with antibodies against STAT3 (1:100 diluted, Santa-
Cruz Biotechnology, Heidelberg, Germany) and STAT1
(1:500 diluted, Santa-Cruz Biotechnology, Heidelberg,
Germany) or with isotype antibodies. The sections were
washed with PBS, incubated with HRP-labelled anti-rabbit
IgG antibody (1:2000 diluted, Sigma-Aldrich, Munich, Ger-
many) for 30 min at room temperature and stained with
DAB (3,3'-diaminobenzidine-tetrahydrochloride) sub-
strate solution (Sigma-Aldrich, Munich, Germany) for 1
min. Kidney sections were counterstained for 30 sec with
Gill's hematoxylin and studied microscopically.
To determine the renal expression of C5aR, kidney sec-
tions were permeabilized with 0.1% Triton X-100/PBS for
20 min and blocked with 5% BSA/PBS for 1 h at room
temperature. After washing, the sections were incubated
for 2 h at room temperature with antibody against C5a
receptor (0.2 mg/ml; 1:200 diluted; BD Biosciences,
Erembodegem, Belgium). Isotype antibody (rabbit anti-
mouse IgG; Sigma-Aldrich, Munich, Germany) was used
as a background staining control. The secondary FITC-
labelled anti-rabbit IgG antibody (1:120 diluted; Sigma-
Aldrich, Munich Germany) was added for 40 min. The
sections were washed and examined with a fluorescent
microscope (BM-180 T/PL, Boeco, Hamburg, Germany).
The glomerular binding of IgG antibodies was evaluated
in kidney sections after 40 min incubation with 1:100
diluted sera pooled from healthy mice (normal serum) or
from zymosan-immunized mice (ZY-positive serum). The
latter was obtained on day 21 post-zymosan injection and
contained high titer of anti-zymosan IgG antibodies. Sec-
ondary FITC-conjugated anti-mouse IgG (Fc specific) anti-
body (1:500 diluted, Sigma-Aldrich, Munich, Germany)
was added for 15 min and the binding of IgG antibodies
to gromeruli was examined with a fluorescent micro-
scope.
Statistical analyses
Data are expressed as mean ± SD. Statistical significance of
differences in survival rate was analyzed by two-way
ANOVA test. For paired data Student's t test was used. Dif-
ferences were considered significant when p < 0.05. Statis-
tical analysis was accomplished using InStat3.0 and
GraphicPad Prism 5.0 (GraphPad Software Inc, La Jolla,
California, USA).
Results
Effect of AG-490 on the survival rate, coagulation time and 
C5a, α1-antitrypsin levels
In our previous experiments, shock mice were treated with
AG-490 in doses ranging from 1 to 10 mg/kg and in dif-
ferent schedules [25]. The dose of 5 mg/kg administered
immediately after the injection of zymosan (1 mg/g body
weight) was determined as the most effective in inhibiting
the mortality and was used herein. AG-490 significantly
increased the survival rate of BALB/c mice (Fig. 1A). Four
hours after shock induction, the elevated C5a production
was strongly inhibited in AG-490-treated mice (Figure
1B). The drug administered in healthy mice did not influ-
ence the plasma and peritoneal level of C5a (Figure 1B).
Zymosan-injected mice showed a reduced coagulation
time (Figure 1C) and a reduced serum level of α1-antit-
rypsin (Figure 1D). The administration of AG-490 ren-
dered both parameters to normal values (Figure 1C, D).
AG-490 slightly increased the coagulation time in healthy
mice without having an effect on α1-antitrypsin level (Fig-
ure 1C, D).
Tyrphostin AG-490 inhibits the levels of MIP-1α and 
RANTES and favors IL-10 production in peritoneum and 
plasma
Zymosan injection (1 mg/g body weight) elevated the
level of MIP-1α and RANTES and increased IL-10 produc-
tion in plasma and in peritoneal lavage at 4 h (Table 1).
The administration of AG-490 significantly diminished
the levels of MIP-1α and RANTES and enhanced addition-
ally the production of IL-10 in mice with shock (Table 1).
The substance itself did not markedly change the levels of
the three mediators neither in the peritoneum nor in the
circulation of healthy mice and slightly elevated the
number of peritoneal cells (1.32 ± 0.15 × 106 cells/ml in
control group versus 1.60 ± 0.09 × 106 cells/ml; p > 0.05).
Tyrphostin AG-490 increases the number of IL-10 secreting 
cells in peritoneum
In order to determine which population is responsible for
the enhanced IL-10 secretion in peritoneum, the cellsJournal of Inflammation 2009, 6:13 http://www.journal-inflammation.com/content/6/1/13
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were separated into two populations: non-adherent and
adherent peritoneal cells (Table 2). In healthy mice we
were not able to detect IL-10-producing cells even after
zymosan stimulation in vitro. IL-10-secreting cells were
found in non-adherent cell population 4 h after zymosan
injection, but more IL-10 producers appeared in adherent
cell population. The number of IL-10-secreting adherent
peritoneal cells increased after zymosan restimulation in
vitro. The administration of AG-490 enhanced the
number of IL-10 producing cells in non-adherent and in
adherent peritoneal populations. In AG-490-treated mice,
the zymosan restimulation of peritoneal cells did not
markedly change the number of IL-10 producers.
Tyrphostin AG-490 inhibits the zymosan-induced kidney 
dysfunction
The plasma level of creatinine started to increase after day
1 of zymosan injection. The highest levels of creatinine
Effect of AG-490 on zymosan-induced inflammation Figure 1
Effect of AG-490 on zymosan-induced inflammation. A, The administration of AG-490 (5 mg/kg) increased the survival 
rate of mice injected with 1 mg/g body weight of zymosan (n = 15/group). B, AG-490 inhibited the level of C5a in peritoneal 
lavage and in plasma 4 h after zymosan injection. C-D, AG-490 rendered the time of coagulation and the plasma level of α1-
antitrypsin to normal range 4 h after the induction of shock. The data represent mean ± SD from 3 independent experiments 
with 5 mice/group; *p < 0.05, **p < 0.01 and ***p < 0.001; Control groups of healthy mice were treated with vehicle (control) 
or AG-490 (AG-490), shock mice were treated with vehicle (ZY) or with AG-490 (ZY+AG-490); ANOVA test was used to 
analyze the survival data and Student's t test to compare other parameters.Journal of Inflammation 2009, 6:13 http://www.journal-inflammation.com/content/6/1/13
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were detected in plasma on day 21 and were completely
abolished in AG-490-treated mice (Figure 2A). The pro-
teinuria developed progressively from day 7 to day 21 of
shock induction and was reduced in AG-490-treated mice
(Figure 2B). The glomerular lesions (Figure 2Ca, see
arrows), the massive cell infiltration in renal medulla (Fig-
ure 2Da, see arrows), the intensive tubular necrosis (Fig-
ure 2Ea, see arrows) were seen in kidneys of zymosan-
injected mice. Histopathological analysis showed the loss
of glomerular structure in 10% of injured kidneys (score
2.1 ± 0.1; Table 3) and the cell influx in medulla and cor-
tex of more than 75% of kidneys (score 5.0 ± 0.2; Table 3).
The administration of AG-490 significantly reduced the
score of renal injury (Table 3). Glomerular lesions were
nearly absent in AG-490-treated mice (Figure 2Cb, score
0.50 ± 0.05; Table 3). The cell infiltration and tubular
injury were less severe in result of AG-490 administration
(Figure 2Db, Eb; Table 3).
Tyrphostin AG-490 inhibits the plasma levels of IL-6 and 
MIP-1α and the renal expression of STAT1 and STAT3
At late stage of shock, AG-490 diminished the plasma lev-
els of IL-6 (Figure 3A) and MIP-1α (Figure 3B). No
changes were noticed in healthy mice injected with AG-
490 (data not shown). Since circulating cytokines can trig-
ger JAK/STAT pathways in kidneys, we evaluated the renal
expression of STAT3 and STAT1 molecules. Immunohisto-
logical analyses showed the positive staining with anti-
STAT1 antibodies of kidneys from shock mice (Figure
3C). STAT3 was detected in shock kidneys at low levels
and predominantly in infiltrating cells (Figure 3D). AG-
490 decreased the zymosan-induced expression of STAT1
and completely inhibited the STAT3 levels in kidneys (Fig-
ure 3C, D).
Tyrphostin AG-490 attenuates the renal injury in SCID 
mice
In order to evaluate the role of acquired immunity for
zymosan-induced renal injury, SCID mice (without func-
tional B and T cells) and BALB/c mice were injected with
0.8 mg/g body weight of zymosan. On day 21 SCID mice
showed significantly increased kidney size, compared to
the control group of healthy animals (Figure 4A). AG-490
diminished the kidney enlargement in 70% of shock mice
and prevented the loss of glomerular structure induced by
zymosan (Figure 4B). Notably, the glomerular lesions
were exhibited more often in SCID mice than in BALB/c
mice (score of glomerular lesions 3.4 ± 0.1 in SCID mice
versus score 1.5 ± 0.2 in BALB/c mice; Figure 4C).
Tyrphostin AG-490 inhibits plasma C5a level and C5aR 
expression in kidneys
On day 21 AG-490 significantly inhibited the high
amount of C5a in circulation of shock mice (Figure 5A).
Table 1: Effect of AG-490 on the MIP-1α, RANTES and IL-10 levels in peritoneum and plasma
Groupsa MIP-1α (pg/ml) RANTES (pg/ml) IL-10 (pg/ml)
peritoneum plasma peritoneum plasma peritoneum plasma
Control 120 ± 28 140 ± 28 145 ± 18 80 ± 20 20 ± 2.0 30 ± 1.8
AG-490 120 ± 30 116 ± 15 125 ± 20 65 ± 15 25 ± 2.0 28 ± 2.0
ZY 1200 ± 58 800 ± 48 580 ± 40 220 ± 35 780 ± 88 420 ± 45
ZY+AG-490 280 ± 36* 380 ± 36* 360 ± 50* 160 ± 30 920 ± 86* 640 ± 54*
aThe peritoneum and plasma level of mediators was determined in healthy mice treated with vehicle (Control) or AG-490 (AG-490) and in shock 
mice treated with vehicle (ZY) or AG-490 (ZY+AG-490). The plasma and peritoneal fluid were collected 4 h after zymosan injection. Data are 
expressed as mean ± SD (n = 5/group) and were compared by Student's t test. *p < 0.01 versus zymosan-injected group.
Table 2: Effect of AG-490 on the number of IL-10-producing cells in peritoneum
Cell populationsa Treatmentb IL-10 producing cells (spots/1.0 × 105cells)c
unstimulated ZY-stimulated
Non-adherent peritoneal cells Control N.D. N.D.
ZY 4.0 ± 1.0 6.0 ± 2.8
ZY + AG-490 9.0 ± 3.1* 10.0 ± 5.5
Adherent peritoneal cells Control N.D. N.D.
ZY 12.7 ± 6.8 27.0 ± 8.9
ZY + AG-490 20.5 ± 4.5** 27.2 ± 7.2
aPeritoneal cells were isolated 4 h after shock induction and were separated in non-adherent and adherent cell populations.
bELISPOT assay was used to determine the number of IL-10-producing cells in peritoneal lavage from healthy mice (Control), untreated (ZY) or 
treated with AG-490 (ZY+AG-490) mice with shock. N.D denotes not detectable.
cCell populations were cultured for 18 h in the absence (unstimulated) or the presence (ZY-stimulated) of zymosan.
Data are expressed as mean ± SD (n = 5/group) and were compared by Student's t test.
**p < 0.01 and *p < 0.05 versus zymosan-injected group.Journal of Inflammation 2009, 6:13 http://www.journal-inflammation.com/content/6/1/13
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In the group of AG-490-treated healthy mice the level of
C5a was similar to the untreated healthy controls (data
not shown). Immunohistochemical analysis of kidney
sections from mice with shock revealed positive staining
for C5a receptor in glomeruli (Figure 5Ba) and in tubular
epithelial cells (Figure 5Bb). In glomeruli, C5aR expres-
sion was detected on infiltrating cells (see arrows). The
C5aR expression was nearly undetectable in kidneys of
AG-490-treated mice (Figure 5Bc, d).
Tyrphostin AG-490 inhibits the level of zymosan-specific 
IgG antibodies and affects IgGs binding to renal glomeruli
The circulating zymosan-specific IgG antibodies were
determined in mice with zymosan-induced shock on day
21 that was significantly inhibited in AG-490-treated mice
(Figure 5C). In respect to kidneys, immunohistochemistry
analyses in shock mice revealed the recognition of the
glomerular structure by IgGs pooled from zymosan-
immunized mice (ZY-positive serum; Figure 5Db). In con-
trol sections, IgGs from healthy mice (normal serum; Fig-
ure 5Dd) did not bind to glomeruli. In AG-490-treated
mice, neither normal nor ZY-positive sera bound to
glomeruli (Figure 5Da, c). After examination of 30
glomeruli/mice, the positive staining was observed in 1 of
5 mice from AG-490-treated group.
Discussion
In the present study we have estimated the effect of JAK2
inhibitor tyrphostin AG-490 on zymosan-induced inflam-
mation with focus on kidney dysfunction. Tyrphostin AG-
490 increased the survival and attenuated the initial phase
of shock by inhibition of MIP-1α and RANTES produc-
tion. AG-490 enhanced IL-10 levels and the numbers of
IL-10 producing peritoneal cells in shock mice. IL-10-pos-
itive spots were found in non-adherent and in adherent
peritoneal cell populations. In non-adherent population,
B-1 cells are most likely the source of IL-10. These cells
constitute 10–15% of the total peritoneal cell pool,
express high levels of surface IgM and downregulate mac-
rophage effector functions such as phagocytosis and
cytokine production [29]. In our study, the adherent peri-
toneal cells contributed to the enhanced IL-10 levels in
peritoneum. Recently, it has been shown that the deple-
tion of resident macrophages (but not monocytes) in IL-
10 deficient mice with shock resulted to an intensive accu-
mulation of polymorphonuclear cells (PMNs) in perito-
neum [30]. In AG-490-treated mice 4 h after zymosan
injection we detected an increased number of IL-10-pro-
ducing adherent cells along with an abolished neutrophil
influx. However, it should be considered that the strongly
elevated IL-10 levels are not always beneficial for the dis-
ease as they can inhibit cell-mediated immunity, can
induce immunosuppression, T cell anergy and tolerance
that can worsen the symptoms of disease.
Recent study provided an evidence for an interaction
between complement system and TLR2 pathway [31]. In
this investigation, TLR2/6 signalling leading to NF-kB acti-
vation was enhanced by the anaphylatoxin receptors
C5aR and C3aR resulting in complement-dependent ele-
vation of plasma TNF-α and IL-6 levels. In the initial
phase of zymosan-induced shock we found an excessive
generation of C5a in plasma and in peritoneal lavage.
High levels of circulating C5a can affect the coagulation
directly or indirectly via cytokines [32,33]. In AG-490-
treated mice the normal coagulation time was found
together with decreased C5a plasma level. The appropri-
ate activation of pro-thrombin system in AG-490-treated
mice was attended by normal levels of acute phase protein
α1-antitrypsin. This protein is a regulator of coagulation
that inhibits the activation of protein C and inactivates
harmful extracellular elastase [33].
Increased STAT3 expression in kidneys has been detected
during severe oxidative stress [34] and glomerulonephritis
[35]. The contribution of STAT1, STAT4 and STAT6 for
renal pathology has also been provided [36,37]. Based on
these studies, the strategies limiting the activation of JAK/
STAT pathway may represent a novel approach to treat
renal diseases. The abnormalities in kidneys were poorly
described in zymosan-induced shock and the renal dys-
function was monitored mainly by changes in creatinine
level [6]. In our study, the alteration in the glomerular fil-
tration rate was found when the plasma level of creatinine
was strongly increased. The administration of AG-490
diminished the amounts of plasma creatinine and pre-
vented further development of proteinuria. These effects
of tyrphostin were accompanied with the lack of changes
in the glomerular structure and with decreased leukocyte
infiltration, tubular dilation and vacuolization and inhib-
ited STAT1 and STAT3 expression. Consistent with our
data are the findings in models of nephritic syndrome and
of renal ischemia/reperfusion injury showing the inhib-
Table 3: Histology examination of kidney damage
Characteristicsa Groups
ZY ZY+AG-490
Glomerular lesions 2.10 ± 0.10 0.50 ± 0.05**
Tubular vacuolization 4.90 ± 0.15 3.60 ± 0.10*
Tubular dilation 2.40 ± 0.10 1.50 ± 0.09*
Tubular necrosis 1.50 ± 0.05 0.50 ± 0.09*
Leukocyte infiltration 5.00 ± 0.20 2.95 ± 0.15**
Renal injury scoreb 15.00 ± 2.20 9.05 ± 2.15**
aKidneys were collected on day 21 of zymosan injection from 
untreated (ZY) or treated with AG-490 (ZY+AG-490) mice.
bThe renal injury score was calculated as an average score of the 
mean score for each characteristic. Data are calculated according to 
the examination of 30 sections/mice (n = 5/group) in 2 experiments. 
The results are expressed as mean ± SD and are compared by 
Student's t test. **p < 0.01 and *p < 0.05 versus zymosan-injected 
group.Journal of Inflammation 2009, 6:13 http://www.journal-inflammation.com/content/6/1/13
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ited STAT1 and STAT3 expression and phosphorylation in
kidneys after AG-490 administration [22,23]. STAT1 and
STAT3 are activated in renal cells or in infiltrating effectors
after cytokine receptors ligation [38]. In macrophages,
TLRs signalling can interfere with the JAK/STAT cytokine
pathways [39]. TLR2 synergizes with IFN-γ-induced STAT1
gene expression and suppresses IL-10-induced STAT3 acti-
vation [40]. In respect to kidneys, TLR2 was found to be
constitutively expressed on human and mouse kidneys
and TLR2 deficiency protects from the renal ischemia-
Effect of AG-490 on kidney dysfunction induced by zymosan Figure 2
Effect of AG-490 on kidney dysfunction induced by zymosan. A, The drug inhibited the plasma level of creatinine. B, 
AG-490 prevented the development of proteinuria. The data represent the mean ± SD from 3 independent experiments 
including 5 mice/group; **p < 0.01 and ***p < 0.001 versus zymosan-injected group; Student's t test. C-E, Histological evalua-
tion of kidneys. The representative data from 2 experiments (n = 5/group) showed glomerular lesions (indicated with arrows 
on Ca; 1 × 400), massive cell infiltration in renal medulla (indicated with arrows on Da, 1 × 400) and tubular necrosis (indicated 
with arrows on Ea; 1 × 400) in shock mice (ZY) on day 21 of zymosan injection. The described pathology was not found in AG-
490-treated mice (Cb, Db, Eb; ZY+AG-490).Journal of Inflammation 2009, 6:13 http://www.journal-inflammation.com/content/6/1/13
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Effect of AG-490 on the production of IL-6 and MIP-1α in plasma and on the renal expression of STAT1 and STAT3 Figure 3
Effect of AG-490 on the production of IL-6 and MIP-1α in plasma and on the renal expression of STAT1 and 
STAT3. A-B, AG-490 diminished the plasma levels of IL-6 and MIP-1α on day 21 of zymosan injection. The data represent the 
mean ± SD from 3 independent experiments (5 mice/group); *p < 0.05 and **p < 0.01 versus zymosan-injected group; Stu-
dent's t test. C-D, The representative data from 1 experiment (n = 5/group) showed increased STAT1 (indicated with arrows 
on C; 1 × 400) and STAT3 expression in kidneys (indicated with arrows on D; 1 × 400) on day 21 of zymosan injection (ZY 
group). The administration of AG-490 decreased the renal expression of both transcription factors (C-D; ZY+AG-490).Journal of Inflammation 2009, 6:13 http://www.journal-inflammation.com/content/6/1/13
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reperfusion injury [41]. However, more data showing the
crosstalk between TLR2 and JAK/STAT pathways in kid-
neys are required.
Previously, we have observed that AG-490 substantially
reduced the elevated serum levels of TNF-α induced by
zymosan. Thus, tyrphostin can influence shock develop-
ment directly or indirectly through TNF-α action on other
cytokines [25]. We established that on day 21 of shock
AG-490 inhibited the plasma level of pro-inflammatory
MIP-1α and IL-6. These mediators in circulation probably
can contribute to the zymosan-induced kidney dysfunc-
tion. MIP-1α binds to chemokines receptors CCL1 and
CCL5 expressed on differentiated macrophages [42]. In
kidneys, MIP-1α can provoke the massive accumulation
of macrophages and can maintain the renal injury [43].
T cells actively participate in renal injury. They are mainly
with Th1 phenotype and produce TNF-α and IFN-γ [44].
The contribution of Th1 cells in renal pathology has been
well described in T bet deficient animals, which lack a
transcription factor promoting Th1 cell differentiation
[45]. The data about the role of B cells in kidney disease
are limited. Recent studies have shown that B-cell defi-
ciency protected the mice from ischemic injury [46] and
that the number of CD19+ B cells was decreased in dam-
aged glomeruli [44]. In order to elucidate whether the
acquired immunity contributes to zymosan-induced
inflammation we have used SCID mice. The lack of func-
tional T and B lymphocytes during shock progression
resulted in the increased mortality and in exacerbation of
organ injury. On day 21 we detected greater kidney
enlargement than in normal mice in parallel with elevated
serum creatinine, tubular injury and intestitial inflamma-
tion. Importantly, glomerular lesions occurred more often
in SCID mice than in BALB/c mice. We suggest that T and
B cells may protect kidneys from renal injury and may
play a critical role for the self-defense mechanisms in
Influence of AG-490 on zymosan-induced kidney damage in SCID and in BALB/c mice Figure 4
Influence of AG-490 on zymosan-induced kidney damage in SCID and in BALB/c mice. A, B, The administration of 
AG-490 reduced the kidney enlargement and prevented the abnormalities in glomerular structure in SCID and BALB/c mice on 
day 21 post-zymosan injection. C, The score of glomerular lesions was higher in SCID mice than in BALB/c mice. Data were 
expressed as mean ± SD from 2 independent experiments with 5 mice/group *p < 0.05, **p < 0.01 versus mice with shock; 
Student's t test.Journal of Inflammation 2009, 6:13 http://www.journal-inflammation.com/content/6/1/13
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Effect of AG-490 on plasma C5a and zymosan-specific IgG antibody levels, on C5aR expression in kidneys and on the IgGs  binding to glomeruli Figure 5
Effect of AG-490 on plasma C5a and zymosan-specific IgG antibody levels, on C5aR expression in kidneys and 
on the IgGs binding to glomeruli. A, AG-490 diminished the level of circulating C5a on day 21 post-zymosan injection. 
AG-490 inhibited C5aR expression in kidneys. Infiltrating cells in glomeruli, Ba and tubular epithelial cells, Bb of shock kidneys 
were positive for C5aR staining (arrows). Bc, d, The renal C5aR expression was undetectable in AG-490-treated mice; 1 × 400; 
*p < 0.05 versus mice with shock, Student's t test. C, Zymosan injection induced anti-zymosan IgG antibodies production that 
was significantly inhibited by AG-490; **p < 0.01 versus zymosan injected group. The results are expressed as mean ± SD of 5 
mice per group from 2 experiments. D, The representative data from 2 experiments showed the glomerular binding of IgGs 
isolated from zymosan-immunized mice (b, d, ZY-positive serum) but not of IgGs isolated from healthy mice (a, c; normal 
serum). Arrows showed the areas of positive staining.Journal of Inflammation 2009, 6:13 http://www.journal-inflammation.com/content/6/1/13
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glomeruli. This hypothesis has been partially supported
by recent study showing the attenuated renal inflamma-
tion after the reconstitution of CD4+ T cells [47]. How-
ever, more investigations are required to understand the
role of T and B cells in zymosan-induced kidney dysfunc-
tion and in the self-defence machinery.
IL-6 causes an increased expression of C5aR in various
organs, such as lung, liver, kidney and heart during CLP-
induced sepsis. The inhibition of IL-6 leads to reduced
expression of C5aR and increased survival [48]. IL-6
upregulates C5aR on myeloid (thymocytes, macrophages,
neutrophils) and on nonmyeloid (epithelial cells,
endothelial cells) cells in lung, liver and kidney [49,50].
On day 21 plasma C5a level remained higher in shock
mice, although not so extremely elevated as it was at first
4 hours. The administration of AG-490 strongly reduced
circulating C5a and inhibited C5aR expression on tubular
epithelial cells on day 21. In AG-490-treated mice, the
negative staining for C5aR in glomeruli was related to
inhibited influx of cells expressing C5aR. Low level of
C5aR can prevent further activation of tubular epithelial
cells and can inhibit the local production of pro-inflam-
matory mediators IL-8, IL-6, TNF-α, MCP-1 and RANTES,
the expression of adhesion molecules and the additional
activation of complement cascade [48]. While neutrophils
loose immediately the surface C5aR in result of C5a/C5aR
internalization [51], macrophages exerted strong
responses after C5aR ligation [52]. Further study should
be conducted to clarify which population expressing
C5aR, macrophages or neutrophils is predominantly
affected by AG-490 administration.
The AG-490 treatment significantly diminished the level
of anti-zymosan IgGs showing the inhibited B cell func-
tions. The role of IgG antibodies in the pathology of
glomerulonephritis has been well documented [53]. The
glomerular injury is induced by the deposition of IgG
antibodies, the formation of immune complexes and the
activation of complement [54] or by the engagement of Fc
fragments of IgGs with cells expressing Fcγ R at the inflam-
matory site [55]. Based on these reports, the question
whether anti-zymosan IgG antibodies can trigger immune
reactions in kidney became intriguing. Immunohisto-
chemistry analyses showed that IgGs pooled from
zymosan-immunized mice were able to recognize some
kidney structures in shock mice, unlike IgGs from healthy
mice. This binding was observed in 10% of glomeruli with
detected structural abnormalities. We suggest that new
immunogenic structures can be exposed in a result of kid-
ney damage. The antigen mimicry and the epitope spread-
ing are common phenomena for autoimmune diseases
such as rheumatoid arthritis and diabetes and are usually
responsible for the perpetuation of inflammatory
immune responses [56]. Similar events can occur in kid-
neys at the late stage of shock since zymosan induced
renal injury in parallel with antibody production. How-
ever, the implications of anti-zymosan IgGs in kidney dys-
function induced by zymosan remain to be elucidated.
Conclusion
In the present study, we have observed that AG-490 inhib-
ited zymosan-induced kidney dysfunction via decrease of
creatinine level, prevention of glomerular structural dam-
ages and proteinuria. These effects were also mediated by
reduced levels of pro-inflammatory MIP-1α and IL-6 and
inhibited renal STAT1 and STAT3 expression. Our results
provide new data on the important role of C5a/C5aR, T
and B cells for the development of renal injury in
zymosan-induced shock.
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